Unlocking Long-Term Immunity Testing.
Building on our successful visualisation of memory B cells we’ve now developed a double marker test to identify memory B cells specific to a pathogen.
Using SARS-CoV-II as a model we’ve been able to trap and tag memory B cells with specificity to bind the SARS-CoV-II nucleocapsid protein. The outcome:
A new single day assay for direct measurement of long-term immunity to a pathogen.
Call to Action
We’re looking for pilot and early adopters looking to add value and improved data for development of their vaccine candidates and vaccines in trial.
With a small amount of optimisation for the client specific detection needs we’re in a position to offer PhenoDot as a long-term immunity detection assay as an RUO tool for measuring the efficacy of vaccines and vaccine candidates in development.
Down to single cell resolution enables us to see cells normally found in scarce numbers.
The sensitivity of PhenoDot is a game changer for detection of long-term immunity as they’re typically cells found in low abundance as low as 0.2% but generally considered between 1 to 2% of PBMC (peripheral blood mononuclear cells). With PhenoDot we’re able to specifically tag and visualise individual cells of interest whilst maintaining very low false positives.
PhenoDot enables a single day solution for testing of long-term immunity to a pathogen. This means easier testing for effective conference of long-term immunity as result of a vaccination or prior infection.
Our goal, to develop the tools for the next generation of vaccines to be developed with a clear measured, tested, and confirmed conference of long-term immunity.
Nucleocapsid protein specific memory B cells
Negative sample.
Why testing long-term immunity is so important.
In the aftermath of COVID-19 there has been great emphasis on our industry to improve and develop vaccines, treatments, and diagnostic tools that will help us respond more quickly and greatly reduce the risk to life of a “Disease X” outbreak.
Testing long-term immunity means we can ensure the efficacy of our responses to another pandemic scenario and at the same time can enable a whole new era of better tested and proven vaccines.
Who is calling for action and what do they need?
World Health Organisation.
“In addition to considering speed and cost, preparation for the next pandemic must consider QUALITY, EQUITY, and TRUST as essential values.”
Philip Krause (key advisor to the WHO)
Coalition for Epidemic Preparedness Innovations.
“We don’t know when or where the next Disease X will strike, only that it will. CEPI is advancing global R&D efforts so the world is better prepared to tackle a Disease X, within 100 days of its identification."
United Kingdom Health Security Association (UKHSA).
Some of the targets over the coming years for UKHSA include
““1. Be ready to respond to all hazards to health.
to prevent and mount scalable and agile responses to health security threats, including pandemics.”
“2. Improve health outcomes through vaccines.
to facilitate innovation in the development of safe and effective vaccines.”
”3. Reduce the impact of infectious diseases and antimicrobial resistance.
minimise the impact of infectious disease”
How can PhenoDot make a difference?
More Accurate
Our long-term immunity test offers clear unmistakable results measuring long-term immunity by double detection ensuring highly specific results with ultra-low false positive counts and direct detection of memory B-cells.
Faster
Direct detection without the need for cell differentiation puts our PhenoDot assay clearly ahead of alternative affordable solutions requiring 7 days and offering only indirect results.
Reduced Costs
The low-tech nature of all PhenoDot based immunoassays means equipment, staff training, and laboratory overheads including labor are greatly reduced.
Flexibility
Highly adaptable for testing current vaccines, pathogens, and new vaccine candidates in development also. Also with the potential to run in minimally equipped facilities its much more accessible to decentralise vaccine testing and attain a much broader population base for testing.